Introduction
============

Asthma and COPD are common chronic inflammatory airway diseases that are responsible for a large burden of illness worldwide. Exacerbations of asthma and COPD are defined as periods of acute deterioration of symptoms and lung function that can result in hospitalization and increased health care utilization and are a major cause of death.[@b1-copd-12-541],[@b2-copd-12-541] Exacerbations impose a substantial economic burden and result in a faster decline in lung function[@b3-copd-12-541],[@b4-copd-12-541] and poorer quality of life.[@b5-copd-12-541],[@b6-copd-12-541] Some patients experience frequent exacerbations[@b4-copd-12-541],[@b7-copd-12-541],[@b8-copd-12-541] that require more effective management strategies. Although some clinical factors have been identified to be associated with frequent exacerbations of asthma[@b2-copd-12-541],[@b9-copd-12-541] and COPD,[@b10-copd-12-541] the underlying mechanisms, including the role of innate immunity in frequent exacerbations, are not well established. If the activation of certain inflammatory pathways was predictive of exacerbations, this would permit both disease monitoring using biomarkers and novel approaches to treatment.

Inflammation in COPD and asthma has airway and systemic components.[@b11-copd-12-541],[@b12-copd-12-541] Low-grade systemic inflammation is associated with a rapid decline in lung function,[@b13-copd-12-541] increased mortality,[@b14-copd-12-541] and a higher exacerbation rate.[@b15-copd-12-541],[@b16-copd-12-541] We have recently shown that the presence of systemic inflammation, measured by elevated systemic C-reactive protein (CRP) and interleukin (IL)-6, is predictive of future exacerbations in asthma and COPD.[@b17-copd-12-541] Further to this, systemic inflammation was associated with elevated IL-1β expression in the airways, and this airway--systemic inflammatory axis was predictive of COPD exacerbations.[@b17-copd-12-541]

IL-1β is a typical innate immune cytokine involved in the initiation and persistence of inflammation.[@b18-copd-12-541],[@b19-copd-12-541] IL-1β secretion is increased in stable and exacerbating COPD[@b20-copd-12-541],[@b21-copd-12-541] and asthma.[@b19-copd-12-541],[@b22-copd-12-541] We previously reported that airway IL-1β is associated with systemic inflammation in asthma.[@b12-copd-12-541],[@b19-copd-12-541],[@b22-copd-12-541] IL-1β gene expression[@b23-copd-12-541] and activation of the IL-1 signaling pathway[@b19-copd-12-541] in sputum are associated with airway neutrophilia and inflammasome activation[@b24-copd-12-541] in asthma. To extend our findings of the predictive relationship of IL-1β and future exacerbations of airway disease,[@b17-copd-12-541] this study assesses selected downstream molecules in the IL-1 signaling pathway. We hypothesized that the activation of the IL-1 pathway is predictive of exacerbations of asthma and COPD, and that these mediators could be used as a biomarker to assess future risk and identify novel therapeutic targets. We, therefore, measured gene expression of selected IL-1 pathway members in our previously conducted prospective cohort study of older people with asthma and COPD[@b17-copd-12-541] and conducted a statistical analysis to explore the predictive nature of IL-1 pathway activation and future exacerbations.

Methods
=======

Study population
----------------

Patients (n=152) with doctor-diagnosed asthma (n=63) or COPD (n=89) were recruited from research registers, as previously reported.[@b17-copd-12-541] Asthma was confirmed by current (past 12 months) episodic respiratory symptoms, doctor's diagnosis, and prior demonstrated evidence of airway hyperresponsiveness to hypertonic saline and/or increased bronchodilator response, according to American Thoracic Society guidelines.[@b25-copd-12-541] COPD was diagnosed according to the Global Initiative for COPD criteria.[@b26-copd-12-541] Participants gave written informed consent and the Hunter New England Local Health District Human Research Ethics Committee approved this study. Exclusion criteria included primary respiratory disorders other than asthma and COPD, or current malignancy. An exacerbation in the past month was a cause to delay visits until recovery (4 weeks of stability). Ex-smokers were defined as those having stopped smoking for 6 months or more prior to their participation in this study.

Study design and protocol
-------------------------

This prospective cohort study was conducted between October 2010 and December 2012, and was previously reported.[@b17-copd-12-541] After baseline assessment, telephone reviews were conducted with participants to assess medication use and exacerbations every 3 months for 12 months.

Baseline assessment
-------------------

Participants attended a baseline visit to assess demographics, smoking status, exacerbation history in the preceding year, medical history, medication use, and visual analog scale symptom score. Pre- and post-bronchodilator spirometry, sputum induction,[@b27-copd-12-541] and venipuncture with blood collection were performed as described.[@b17-copd-12-541]

Exacerbation capture
--------------------

Respiratory hospitalizations, emergency room (ER) visits, unscheduled general practice visits, and medication use including antibiotics and systemic corticosteroids were recorded at each assessment. An exacerbation of COPD was defined as a COPD-related episode with, 1) hospitalization, 2) ER visit, or 3) the need for oral corticosteroid (OCS) and/or antibiotics for at least 3 days.[@b8-copd-12-541] An exacerbation of asthma was defined using the severe asthma exacerbation criteria of the American Thoracic Society/European Respiratory Society Task Force,[@b28-copd-12-541] or an asthma exacerbation with lower respiratory tract infection requiring antibiotics.[@b29-copd-12-541] A frequent exacerbator was defined as a participant with ≥2 exacerbations,[@b8-copd-12-541],[@b30-copd-12-541] whereas infrequent exacerbators had \<2 exacerbations during the follow-up period.

Gene expression analysis
------------------------

Sputum gene expression was measured on 95 subjects who had sputum stored for RNA analysis using quantitative real-time polymerase chain reaction (qRT-PCR) as previously described.[@b19-copd-12-541],[@b23-copd-12-541] Briefly, sputum RNA was extracted using the RNeasy Mini Kit (QIAGEN, Hilden, Germany), and 200 ng of RNA was converted to complementary DNA (cDNA) using the High Capacity cDNA RT-PCR kit (Life Technologies) and used to detect relative gene expression using standard Taqman methods (Applied Biosystems, Foster City, CA, USA). IL-1 pathway mediators were selected for measurement (previously identified as differentially regulated),[@b19-copd-12-541],[@b23-copd-12-541] including the signaling receptor *IL1R1*, the decoy receptor *IL1R2*, the antagonist *IL1RN*, and signaling molecules *IRAK2*, *IRAK3*, and *PELI1*. Statistical analysis was performed on the change in cycle threshold (ΔCt) between the target gene and β-actin (housekeeping gene). Fold-change results were calculated using 2^−ΔΔCt^ relative to both the housekeeping gene (β-actin) and the mean of all samples.

Statistical analysis
--------------------

Data were analyzed using STATA 11.2 (Stata Corp, College Station, TX, USA) and were reported as mean (SD) or median (interquartile range \[25%--75%\]) depending on the distribution. Comparisons between two independent groups were performed using Student's *t*-test or the two-sample Wilcoxon rank sum test as appropriate. Fisher's exact test was used to test categorical data. Receiver operating characteristic (ROC) curves were generated and the area under the curve was calculated to determine predictive relationships as previously described.[@b23-copd-12-541] Associations were tested using Spearman rank correlation. Significance was accepted if *P*\<0.05.

Results
=======

Clinical characteristics and inflammatory cells
-----------------------------------------------

Clinical characteristics and sputum inflammatory cells for the participants are detailed in [Table 1](#t1-copd-12-541){ref-type="table"}. A subset of 95 participants had detailed assessment of clinical characteristics, exacerbation history (prior year) and sputum collected for inflammatory cell counts, and measurement of gene expression of the IL-1 pathway. Of the 95 participants, 89 completed the exacerbation monitoring in the 12 months following their baseline assessment. There were 30 participants who had two or more exacerbations in the year following their baseline assessment, comprising 22 COPD and eight asthma participants. There were 59 individuals who experienced either zero or one exacerbation in the following 12 months, 33 had COPD, while 26 had asthma ([Table 1](#t1-copd-12-541){ref-type="table"}). The distribution of the number of exacerbations recorded over the following 12-month period is shown in [Figure 1](#f1-copd-12-541){ref-type="fig"}. Participants with COPD were older, had a greater degree of airflow limitation, and more frequent past exacerbations than those with asthma ([Table 1](#t1-copd-12-541){ref-type="table"}). Asthma and COPD participants were similar in terms of inhaled corticosteroid use and sputum inflammatory cells.

Gene expression of IL-1 pathway mediators predicts future exacerbations
-----------------------------------------------------------------------

Because of our previously reported associations with IL-1β expression and exacerbation prediction, we further investigated expression of mediators of the IL-1 pathway. At baseline, gene expressions of the IL-1 signaling genes *IRAK2*, *IRAK3*, and *PELI1* and the signaling receptor *IL1R1* were more strongly expressed in the group who had two or more exacerbations (frequent exacerbator group), across the whole combined study population, with a mean fold change of 2.8, 4.6, 2.4, and 3.3, respectively ([Table 2](#t2-copd-12-541){ref-type="table"}; [Figure 2](#f2-copd-12-541){ref-type="fig"}). The higher expressions of *IRAK2*, *IRAK3*, *PELI1*, and *IL1R1* were also seen in both COPD and asthma when analyzed separately ([Table 2](#t2-copd-12-541){ref-type="table"}; [Figure 2](#f2-copd-12-541){ref-type="fig"}). The results were specific for IL-1 signaling because there was no significant difference in the gene expression of the decoy receptor *IL1R2* or the receptor antagonist *IL1RN* ([Table 2](#t2-copd-12-541){ref-type="table"}; [Figure 2](#f2-copd-12-541){ref-type="fig"}). IL1A expression was higher in frequent exacerbators with COPD, but not with asthma ([Table 2](#t2-copd-12-541){ref-type="table"}).

Given the differences in gene expression between groups, the ability of *IRAK2*, *IRAK3*, *PELI1*, and *IL1R1* sputum gene expression to predict future frequent exacerbations was investigated using ROC curves. All markers could significantly predict frequent future exacerbations in the combined group, but also in COPD and asthma separately ([Table 3](#t3-copd-12-541){ref-type="table"}; [Figure 3](#f3-copd-12-541){ref-type="fig"}). *IRAK3* was the best discriminator, followed closely by *IL1R1* and *PELI1* ([Table 3](#t3-copd-12-541){ref-type="table"}; [Figure 3](#f3-copd-12-541){ref-type="fig"}). The level of sputum gene expression of *IRAK2*, *IRAK3*, *PELI1*, and *IL1R1* was correlated with the number of exacerbations experienced by the participants ([Table 4](#t4-copd-12-541){ref-type="table"}).

Type and severity of exacerbations
----------------------------------

The levels of gene expression of the IL-1 pathway mediators were investigated in relation to the type and severity of the exacerbations experienced, including antibiotic courses (two or more, n=27) and OCS courses (two or more, n=17), general practitioner visits (two or more, n=17), and hospital admissions (n=11). Gene expression of IRAK2 was significantly higher in participants who were admitted to hospital for their exacerbation, and in those who had two or more OCS courses ([Figure 4](#f4-copd-12-541){ref-type="fig"}) compared with the nonfrequent exacerbator group. Expressions of IRAK3, PELI1, and IL1R1 were significantly higher in all types of exacerbations compared with the nonfrequent exacerbator group ([Figure 4](#f4-copd-12-541){ref-type="fig"}).

Relationship of IL-1 pathway mediators with prior exacerbations
---------------------------------------------------------------

The relationship between the expression levels of the IL-1 pathway genes in the participants with frequent exacerbations was also investigated. Gene expressions of the IL-1 signaling genes *IRAK2*, *IRAK3*, and *PELI1* and receptor *IL1R1* are more strongly expressed in the participants with previous frequent exacerbations, across the study population and in COPD and asthma separately ([Table 5](#t5-copd-12-541){ref-type="table"}; [Figure 5](#f5-copd-12-541){ref-type="fig"}). *IL1R2* is also more strongly expressed in the frequent exacerbator group across the population and in asthma but not COPD separately, whereas *IL1RN* was significantly higher in the frequent exacerbators only in asthma ([Table 5](#t5-copd-12-541){ref-type="table"}; [Figure 5](#f5-copd-12-541){ref-type="fig"}). IL1A expression was higher in prior year frequent exacerbators with COPD, but not with asthma ([Table 5](#t5-copd-12-541){ref-type="table"}).

Discussion
==========

Severe exacerbations of COPD and asthma lead to rapid health decline and can cause death; preventing severe exacerbations is, therefore, a major treatment goal. The mechanisms underlying exacerbations and their impact are not fully understood, and tools to predict at-risk patients are limited. This study has recorded exacerbations of different types and severities, and linked these to enhanced activation of IL-1 pathway gene expression. This prospective cohort study identifies that gene expressions of airway IL-1 signaling molecules *IRAK2*, *IRAK3*, and *PELI1* and the signaling receptor *IL1R1* are associated with frequent exacerbations and predict exacerbation risk in the obstructive airway diseases COPD and asthma. IL-1 signaling mediators were correlated with the number of exacerbations, and the level of expression was the highest in more severe exacerbations characterized by OCS use or hospital admission. High IL-1 pathway gene expression was also associated with frequent prior year exacerbations. Elevated IL-1 pathway activation is, therefore, potentially both a useful biomarker for exacerbation risk prediction and a novel treatment target for exacerbation reduction in COPD and asthma.

IL-1 family cytokines are major mediators of innate immune responses, controlling proinflammatory reactions to pathogen- or damage-associated molecular patterns.[@b31-copd-12-541] Secretion of active IL-1β requires two signals, the first being an upregulation of IL-1β production through toll-like receptor (TLR) signaling, and either cleavage through the NLRP3 inflammasome or neutrophil proteases. IL-1β then acts through its signaling receptor, IL-1R1, to activate a complex signaling cascade involving the IL-1 receptor-associated kinases IRAK1, IRAK2, and IRAK4, resulting in the activation of transcription factors including nuclear factor-κB (NF-κB) and production of inflammatory cytokines. The decoy receptor IL-1R2 and antagonist IL-1Ra (encoded by *IL1RN*) act to limit this pathway activation through binding IL-1 or IL-1R1, respectively, but not activating a signaling cascade.[@b31-copd-12-541] IL-1/TLR pathway signaling is critical in initiating appropriate innate immune responses to infections, and, therefore, malfunction of this pathway is likely to have negative downstream consequences, for example persistence of infection, heightened inflammation.

IRAK-M (encoded by *IRAK3*) is believed to function as a negative regulator that prevents the dissociation of IRAK-1/2 from the TLR/IL-1 receptor complex, which then inhibits downstream signaling.[@b32-copd-12-541] However, these signaling pathways are complex with multiple mechanisms leading to NF-κB activation, but also regulation of mRNA stability. For example, interaction between IRAK2 and IRAK-M can also mediate NF-κB activation through TLR7, while controlling translation of cytokines and chemokines at the mRNA level.[@b33-copd-12-541] Expression of IRAK-M is induced by lipopolysaccharide and is expressed in predominantly macrophages. Increased expression of IRAK-M occurs in endotoxin tolerance,[@b34-copd-12-541] whereby inflammatory responses to endotoxin are reduced after multiple exposures. Bacterial challenge of IRAK-M-deficient mice produces the elevated levels of cytokines and chemokines in murine lungs.[@b35-copd-12-541] However, overexpression of IRAK-M can enhance rhinovirus replication in human airway epithelial cells by enhancing autophagy.[@b36-copd-12-541] IRAK-M expression can also be induced by noninfectious triggers, for example adiponectin, a cytokine product of adipose tissue.[@b37-copd-12-541] Gene polymorphisms in IRAK-M have been associated with the pathogenesis of early-onset persistent asthma.[@b38-copd-12-541]

The family of pellino proteins are E3 ubiquitin ligases that play an important role in TLR/IL-1 signaling and immune responses.[@b39-copd-12-541] Pellino-1 promotes interactions between the IL-1β and the IRAK4--IRAK1--TRAF6 complex, and mediates NF-κB activation.[@b39-copd-12-541] We have previously reported the upregulation of *PELI1* gene expression that is associated with airway neutrophilia in asthma[@b19-copd-12-541] and recurrent protracted bacterial bronchitis,[@b40-copd-12-541] and rhinovirus infection of COPD, but not healthy primary bronchial epithelial cells.[@b41-copd-12-541] Pellino-1 knockdown in human primary bronchial epithelial cells reduces the production of IL-1β-induced CXCL8, but does not affect responses to viruses.[@b42-copd-12-541] This promisingly suggests that the inhibition of pellino-1 may modulate neutrophilic inflammation without compromising innate immune responses to viral infection.

There are few diagnostic tools presently available that allow clinicians to predict patients who are at high risk of future exacerbations. Airway disease exacerbations are typically associated with neutrophil and sometimes eosinophil influx into the airways;[@b43-copd-12-541] however, we did not find a predictive relationship of inflammatory cell counts and future exacerbations,[@b17-copd-12-541] so this is likely only relevant at the time of exacerbation. We have previously identified that upregulation of IL-1 pathway gene expression is associated with neutrophilic airway inflammation in asthma,[@b19-copd-12-541],[@b23-copd-12-541] and so may be related to neutrophil influx. The presence of systemic inflammation, as measured by circulating CRP and IL-6 levels, is also predictive of exacerbations[@b17-copd-12-541] and associated with airway neutrophilia.[@b22-copd-12-541]

Measurement of these mediators would provide a number of advantages over the current marker of future exacerbation, being past history of exacerbation. These advantages include the measurement being objective, with precise and sensitive quantification using qPCR, with the mediators showing clear upregulation that could be used to target treatment directly to underlying mechanisms. Biomarker measurement will not rely on patient recall, and future studies may demonstrate a role in treatment monitoring, based on the levels of IL-1 mediators.

The presence of airway inflammation is often triggered by infection, including bacteria and viruses. Indeed, elevated IL-1β is a feature of a bacteria-predominant acute exacerbation of COPD[@b21-copd-12-541] and stable neutrophilic asthma.[@b23-copd-12-541] Our study shows that the persistent activation of IL-1 signaling through IL-1R1, IRAK3, IRAK2, and PELI1 influences the future susceptibility of patients to multiple severe exacerbations. Although IL-1 signaling molecules were increased in frequent exacerbators, this was not accompanied by increases in anti-inflammatory actions of IL-1Ra or IL-1R2. The mechanisms underlying these observations need further characterization, as do potential targeted treatments, for example recombinant human IL-1Ra, which inhibits the biological activity of IL-1.[@b44-copd-12-541]

Although we have found promising insight into the mechanisms underlying exacerbations of COPD and asthma, this study has several limitations. As a single-center study with a relatively small sample size, further studies need to be conducted in a larger cohort, across multiple centers to confirm these relationships. We were unable to assess the heterogeneity of inflammation at the time of exacerbations or test the potential triggers of the exacerbations and their relationship to IL-1 pathway mediators. Further studies are required to assess whether IL-1 pathway activation is associated with a particular infectious trigger of exacerbation, for example, bacteria or viruses, and potential mechanisms for the persistence of this type of inflammation once the exacerbation has resolved, and how this impacts on future susceptibility of the patients. We are also unable to determine the effects of common treatments including antibiotics and OCSs on the expression of IL-1 pathway mediators, of interest in understanding potential strategies to reduce exacerbations. Future studies will need to further characterize any differences between the exacerbations of asthma and COPD on the activation of the IL-1 pathway, such as the increased expression of IL1R2 and IL1RN in frequent prior year exacerbations of asthma but not COPD.

In conclusion, we have shown that the upregulation of IL-1 pathway mediators, including the signaling molecules *IRAK2*, *IRAK3*, and *PELI1* and the signaling receptor *IL1R1*, in stable COPD and asthma is associated with frequent exacerbations in the following year, as well as the prior year. Expression of IL-1 pathway mediators correlated with the number and severity of future exacerbations. Further studies are warranted investigating these mediators as both potential diagnostic biomarkers predicting at-risk patients and novel treatment targets for exacerbation reduction.
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![Histogram showing the distribution of the number of exacerbations experienced in the year following the baseline visit.](copd-12-541Fig1){#f1-copd-12-541}

![Gene expression of the IL-1 pathway signaling members (**A**) IRAK2, (**B**) IRAK3, (**C**) PELI1 and receptor (**D**) IL1R1 were elevated in participants with frequent exacerbations, whereas the decoy receptor (**E**) IL1R2 and antagonist (**F**) IL1RN were not significantly different.\
**Notes:** Data are presented as medians (bar) and the upper quartile (Q3; error bar). \* *P*\<0.05 versus the nonfrequent exacerbator group; ^\#^ *P*\<0.05 versus the nonfrequent exacerbator group with COPD; and ^\^^ *P*\<0.05 versus the nonfrequent exacerbator group with asthma.\
**Abbreviation:** IL, interleukin.](copd-12-541Fig2){#f2-copd-12-541}

![Receiver operating characteristic curve analysis of interleukin 1 signaling pathway gene expression and future exacerbations in (A) the whole study population, (B) COPD, and (C) asthma.](copd-12-541Fig3){#f3-copd-12-541}

![Gene expression of IL-1 pathway members (**A**) IRAK2, (**B**) IRAK3, (**C**) PELI1 and (**D**) IL1R1 are associated with exacerbation type.\
**Notes:** Gene expression is highest in the OCS and hospital admission groups. Data is presented as medians (bar) and the upper quartile (Q3; error bar). \* *P*\<0.01 versus the non-frequent exacerbator group; \*\* *P*\<0.001 versus the non-frequent exacerbator group.\
**Abbreviations:** Ab, antibiotics; OCs, oral corticosteroids; GP, general practitioner.](copd-12-541Fig4){#f4-copd-12-541}

![Gene expression of IL-1 pathway members are elevated in participants who had ≥2 exacerbations (frequent) in the year prior to the baseline visit. Data is presented as median (bar) and the upper quartile (Q3; error bar). \* *P*\<0.05 versus the non-frequent exacerbator group; ^\#^ *P*\<0.05 versus the non-frequent exacerbator group with COPD; and \^ *P*\<0.05 versus the non-frequent exacerbator group with asthma.](copd-12-541Fig5){#f5-copd-12-541}

###### 

Baseline clinical and inflammatory characteristics for the participants included in the gene expression substudy

                                                                          COPD + Asthma        COPD                 Asthma               *P*-value[a](#tfn1-copd-12-541){ref-type="table-fn"}
  ----------------------------------------------------------------------- -------------------- -------------------- -------------------- ------------------------------------------------------
  n (%)                                                                   95                   60                   35                   
  Age, mean (SD)                                                          65 (12)              68 (10)              60 (15)              0.004
  Gender, n, male/female                                                  39/56                25/35                14/21                0.873
  Body mass index, mean (SD)                                              29.6 (7.4)           28.7 (7.1)           31.2 (7.8)           0.226
  Smoking, n, never/ex/current                                            43/46/6              22/34/4              21/12/2              0.076
  Smoking pack-years, median (Q1, Q3)                                     27 (3, 47)           28 (3, 44)           17 (7, 47)           0.720
  Post--β~2~ FEV~1~ %predicted, mean (SD)                                 69 (20)              59 (17)              85 (13)              ,0.001
  Post--β~2~ FVC %predicted, mean (SD)                                    84 (17)              81 (17)              89 (15)              0.032
  FEV~1~/FVC %, mean (SD)                                                 62 (13)              55 (11)              74 (7)               ,0.001
  Airway hyperresponsiveness or bronchodilator response at visit, n (%)   48 (51)              33 (55)              15 (43)              0.254
  Visual analog scale symptom score, mean (SD)                            18.5 (12.1)          19.5 (12.7)          16.8 (11.1)          0.311
  ICS use, n (%)                                                          81 (85)              52 (87)              29 (83)              0.613
  ICS dose, beclomethasone equivalent, µm/day, median (Q1, Q3)            1,000 (500, 2,000)   1,000 (500, 2,000)   1,000 (500, 2,000)   0.812
  Number of exacerbations in the year prior to baseline visit             1 (0, 2)             1 (0, 2)             0 (0, 1)             0.108
  ≥2 exacerbations in the prior year, n (%)                               34 (36)              26 (43)              8 (23)               0.045
  ≥2 exacerbations in the following year, n (%)                           30 (33)              22 (39)              8 (24)               0.110
  Sputum total cell count, ×10^6^/mL, median (Q1, Q3)                     4.1 (2.6, 8.6)       4.3 (2.6, 9.7)       4.0 (2.1, 6.2)       0.363
  Sputum neutrophil%, median (Q1, Q3)                                     47.6 (32.3, 71.8)    59.0 (30.8, 73.9)    45.5 (34.0, 61.8)    0.264
  Sputum eosinophil%, median (Q1, Q3)                                     1.5 (0.5, 3.0)       1.8 (0.8, 3.0)       1.3 (0.5, 2.8)       0.351

**Note:**

Comparison between COPD and asthma.

**Abbreviations:** FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; ICS, inhaled corticosteroid; Q, quartile; SD, standard deviation.

###### 

Sputum gene expression of IL-1 pathway genes in participants with future year frequent versus nonfrequent exacerbations

  Marker[a](#tfn3-copd-12-541){ref-type="table-fn"}   COPD+Asthma   COPD          Asthma                                                                     
  --------------------------------------------------- ------------- ------------- --------- ------------- ------------- ------- -------------- ------------- -------
  n                                                   30            59                      22            33                    8              26            
  IRAK2                                               1.28 (2.63)   2.74 (1.87)   0.003     1.14 (2.83)   2.31 (1.90)   0.073   1.66 (2.13)    3.27 (1.72)   0.035
  IRAK3                                               4.60 (2.56)   6.81 (1.94)   \<0.001   4.33 (2.52)   6.44 (1.96)   0.001   5.35 (2.71)    7.29 (1.83)   0.026
  PELI1                                               2.87 (1.91)   4.15 (1.48)   \<0.001   2.75 (1.88)   3.69 (1.36)   0.037   3.18 (2.07)    4.74 (1.45)   0.022
  IL1R1                                               5.00 (2.24)   6.70 (1.84)   \<0.001   4.95 (2.16)   6.23 (1.48)   0.012   5.14 (2.60)    7.30 (2.08)   0.021
  IL1R2                                               4.45 (3.29)   5.07 (1.89)   0.261     4.44 (3.68)   4.61 (1.74)   0.817   4.47 (2.04)    5.65 (1.95)   0.150
  IL1RN                                               1.80 (4.07)   1.70 (1.60)   0.868     2.30 (4.41)   1.57 (1.57)   0.380   0.042 (2.69)   1.88 (1.65)   0.071
  IL1A                                                5.97 (2.64)   6.83 (1.48)   0.054     5.59 (2.82)   6.96 (1.65)   0.027   7.01 (1.80)    6.64 (1.24)   0.520

**Notes:**

Data expressed as the change in cycle threshold (Ct) compared with the housekeeping gene β-actin (ΔCt), mean (standard deviation). A lower ΔCt corresponds to a stronger expression of the target gene.

**Abbreviation:** IL, interleukin.

###### 

Interleukin 1 signaling pathway gene expression predicts the risk of future frequent exacerbations

  Marker              AUC %   *P*-value   95% CI       Minimal false negatives[a](#tfn5-copd-12-541){ref-type="table-fn"}   Minimal false positives[a](#tfn5-copd-12-541){ref-type="table-fn"}                          
  ------------------- ------- ----------- ------------ -------------------------------------------------------------------- -------------------------------------------------------------------- ------ -------- ------ ------
  **COPD + Asthma**                                                                                                                                                                                                     
  IRAK2               68.6    0.004       0.56--0.81   \<2.70                                                               70.0                                                                 61.0   \<1.59   60.0   78.0
  IRAK3               75.4    \<0.001     0.64--0.87   \<6.44                                                               80.0                                                                 72.9   \<5.24   63.3   79.7
  PELI1               71.2    \<0.001     0.59--0.83   \<3.87                                                               73.3                                                                 62.7   \<3.20   56.7   72.9
  IL1R1               72.8    \<0.001     0.61--0.85   \<6.13                                                               73.3                                                                 64.4   \<5.18   66.7   81.4
  **COPD**                                                                                                                                                                                                              
  IRAK2               66.3    0.042       0.50--0.83   \<2.71                                                               72.7                                                                 57.6   \<0.79   59.1   72.7
  IRAK3               76.0    0.001       0.62--0.91   \<6.44                                                               86.4                                                                 69.7   \<5.12   68.2   81.8
  PELI1               68.6    0.020       0.53 0.84    \<3.48                                                               68.2                                                                 60.6   \<2.74   59.1   78.8
  IL1R1               71.5    0.007       0.56--0.87   \<6.13                                                               77.3                                                                 60.6   \<5.18   68.2   81.8
  **Asthma**                                                                                                                                                                                                            
  IRAK2               72.1    0.062       0.52--0.93   \<3.15                                                               75.0                                                                 50.0   \<1.59   50.0   92.3
  IRAK3               73.6    0.047       0.54--0.93   \<7.56                                                               75.0                                                                 53.9   \<6.36   62.5   76.9
  PELI1               74.0    0.042       0.56--0.92   \<4.51                                                               75.0                                                                 61.5   \<3.92   62.5   76.9
  IL1R1               73.6    0.047       0.54--0.93   \<6.86                                                               75.0                                                                 65.4   \<5.26   62.5   80.8

**Note:**

Minimal false-negative results correspond to the point of the receiver operating characteristic curve with the highest sensitivity (true-positive rate, which is useful for ruling disease out), whereas minimal false-positive results correspond to the point with the highest specificity (false-positive rate, which is useful for ruling disease in).

**Abbreviations:** AUC, area under the curve; CI, confidence interval.

###### 

Correlations between interleukin 1 pathway gene expression and number of exacerbations experienced in the year following the baseline visit

  Marker       Number of exacerbations                                   
  ------------ ------------------------- --------- ------ ------- ------ -------
  IRAK2 mRNA   0.26                      0.009     0.27   0.042   0.31   0.067
  IRAK3 mRNA   0.34                      \<0.001   0.38   0.003   0.28   0.115
  PELI1 mRNA   0.30                      0.004     0.26   0.048   0.35   0.034
  IL1R1 mRNA   0.27                      0.008     0.27   0.036   0.26   0.119

###### 

Sputum gene expression of interleukin 1 pathway genes in participants with prior year frequent versus nonfrequent exacerbations

  Marker   COPD+Asthma   COPD          Asthma                                                                      
  -------- ------------- ------------- --------- ------------- ------------- --------- ------------- ------------- -------
  n        34            61                      26            34                      8             27            
  IRAK2    1.02 (2.10)   2.89 (1.98)   \<0.001   0.85 (2.15)   2.58 (2.14)   0.003     1.58 (1.97)   3.28 (1.72)   0.023
  IRAK3    4.21 (2.18)   6.94 (1.87)   \<0.001   4.03 (2.18)   6.62 (1.85)   \<0.001   4.76 (2.28)   7.34 (1.86)   0.003
  PELI1    2.50 (1.54)   4.27 (1.53)   \<0.001   2.35 (1.41)   3.91 (1.52)   \<0.001   3.00 (1.93)   4.73 (1.45)   0.010
  IL1R1    4.66 (1.73)   6.76 (1.98)   \<0.001   4.68 (1.58)   6.30 (1.82)   \<0.001   4.60 (2.26)   7.32 (2.07)   0.003
  IL1R2    3.96 (3.11)   5.40 (1.93)   0.007     4.11 (3.47)   5.02 (1.97)   0.202     3.46 (1.50)   5.86 (1.81)   0.002
  IL1RN    1.48 (3.91)   1.83 (1.66)   0.549     1.93 (4.12)   1.67 (1.86)   0.747     0.01 (2.89)   2.02 (1.37)   0.009
  IL1A     6.01 (2.28)   6.83 (1.68)   0.050     5.68 (2.27)   6.96 (2.00)   0.024     7.23 (2.05)   6.67 (1.18)   0.344

**Notes:** Data expressed as the change in cycle threshold (Ct) compared with the housekeeping gene β-actin (ΔCt), mean (standard deviation). A lower ΔCt corresponds to a stronger expression of the target gene.
